Clinical evidence, not promises.
22 studies published with hospitals, insurers and universities across 6 countries. Every result is one click from its original paper.
- peer-reviewed papers and preprints
- 22
- million patients analyzed
- 68
- countries with studies
- 6
- research lines
- 5
We validate every model with real-world data and blinded specialists before it reaches the clinic.
- Hospitals
- Insurers
- Universities
Research lines
Five fronts where we measure, with real data, whether AI improves clinical decisions.
Kidney and nephrology
Early detection of chronic kidney disease.
3 studies
Medical imaging
X-ray, CT and OCT combined with clinical data.
4 studies
LLMs and clinical search
Assistants that answer with cited evidence.
7 studies
Clinical data and EHR
Reading clinical records at scale, nuance intact.
6 studies
Population health
Predicting risk across millions of patients at once.
2 studies
Latest research
Filter by research line or review status. Every card leads to the summary and the paper.
Minimal-resource AI Detects CKD in Type 2 Diabetes Patients Across Six LMICs with 90% Sensitivity
90.05% Sensitivity · CKD in type 2 diabetes
KidneyAug 2025 · 5 min
Ensemble AI Detects CKD with 91% Sensitivity in Diabetics and 92.5% in Non‑Diabetics
91% Sensitivity · diabetic patients
Kidney2024 · 5 min
Noninvasive AI Algorithm Boosts Early CKD Detection by Up to 90% in Latin American Patients
+90% More at-risk patients identified (up to)
KidneyAug 2025 · 5 min
Want to validate Arkangel at your institution?
We design the study with you: protocol, ethics committee, de-identified data and joint publication.